Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)
NCT00655967 · University of New Mexico · PHASE4 · withdrawn · last registry update 2023-08-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI left the institution” | – | Registry record, University of New Mexico |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GRIN1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-06-18Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Morphine + IN fentanyl (NCT06464146)
- 2024-05-24Phase 3 first posted: Dr George Medvedev, Eptinezumab (NCT06428838)
- 2024-04-10Results posted on the registry: Washington University School of Medicine, Ketamine + Normal saline (NCT05233566)
- 2023-09-22Phase 3 first posted: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Fentanyl Citrate + Esketamine (NCT06051227)
- 2023-08-23Phase 3 first posted: Inova Health Care Services, Namenda (NCT06007846)
- 2023-04-03Phase 3 first posted: University of Chicago, Memantine (NCT05796752)
- 2023-01-25Phase 3 first posted: The University of Texas Health Science Center at San Antonio, Ketamine Hydrochloride (NCT05696691)
- 2022-11-23Phase 3 first posted: Abraham Nunes, Ketamine + Midazolam (NCT05625555)
- 2022-11-02Phase 3 first posted: Dr. Inge Winter, Clozapine + Esketamine Nasal Product (NCT05603104)
- 2022-10-28Phase 3 first posted: Wake Forest University Health Sciences, Oxycodone + Acetaminophen (NCT05597878)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision